RBC Europe’s Puma Biotechnology PBYI Stock Holding History

RBC Europe’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-93	Closed	-$11.1K	–	1155
2017 Q3	$11.1K	Buy	+93	New	+$8.65K	﹤0.01%	811

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RBC Europe's PBYI Position: Q4 2017 in Review

RBC Europe sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 93 shares — an estimated $11.1K sold.

RBC Europe first reported a position in PBYI in Q3 2017 and held it in 1 quarter. The position peaked at $11.1K in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

RBC Europe reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
RBC Europe sold 93 Puma Biotechnology shares in Q4 2017, an estimated $11.1K.
RBC Europe first reported a position in Puma Biotechnology in Q3 2017 and held it in 1 quarter.
RBC Europe's Puma Biotechnology position peaked at $11.1K in Q3 2017.
203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.